Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions
A Randomized, Single-dose, Open-label, Two-way Crossover Pivotal Study to Assess the Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation (MDI, eq. to Albuterol 90mcg/Puff) and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation (MDI, eq. to Albuterol 90mcg/Puff) in Healthy Volunteers Under Fasting Conditions
Sponsor: Intech Biopharm Ltd.
Listed as NCT04803734, this NA trial focuses on Healthy and remains completed. Sponsored by Intech Biopharm Ltd., it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Apr 2024 — Jul 2024 [monthly]
Completed NA
-
Oct 2023 — Apr 2024 [monthly]
Completed NA
-
Sep 2022 — Oct 2023 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 2 earlier versions
-
Sep 2021 — Sep 2022 [monthly]
Active Not Recruiting NA
Status: Not Yet Recruiting → Active Not Recruiting
-
Apr 2021 — Sep 2021 [monthly]
Not Yet Recruiting NA
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Intech Biopharm Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .